AI company raises $12M for ‘digital twin’ tech aimed at healthcare researchers
Unlearn.AI, a San Francisco-based AI technology company, has raised $12 million in Series A financing. The funding round was led by 8VC, with additional investments coming from DCVC, DCV Bio and Mubadala Capital Ventures.
The financing is expected to go toward ramping up DiGenesis, the company’s machine learning platform that creates “digital twins” for clinical trials. These digital twins function like actual patient records and can be used by researchers to generate effective control patient data.
Unlearn’s early efforts will be focused on improving research related to neurological diseases such as Alzheimer’s Disease.
“This new financing marks an important milestone in our growth and will contribute to the significant progress we are making with regulators and with our commercial partners, who are already running studies with digital twins and demonstrating their value in generating robust evidence and increasing the potential for trial success,” Charles K. Fisher, PhD, founder and CEO of Unlearn.AI, said in a statement. “Clinical trials are facing a number of persistent challenges that have only been exacerbated in recent weeks. With support from our forward-thinking investors and industry partners, we are excited to continue growing our exceptional team and advancing the science behind our first-of-its-kind digital twin approach.”
As a result of this funding round, Francisco Gimenez, PhD, 8VC principal, will now serve on the Unlearn Board of Directors.
“Unlearn's pioneering use of Digital Twins will limit the number of patients that need to go on placebo while also reducing overall trial enrollment time,” Gimenez said in the same statement. “As investors at the intersection of healthcare and technology, we're passionate about companies that pair cutting-edge computational techniques and innovative business models to meaningfully improve patient care.”
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.